Active immunotherapy for non-small-cell lung cancer: Moving toward a reality

Expert Review of Anticancer Therapy

Volumn 11, Issue 10, 2011, Pages 1599-1605

  Perez, Cesar A ^a   Santos, Edgardo S ^a   Raez, Luis E ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Memorial Cancer Institute   (United States)

Author keywords

antigens; EGF; lung cancer; MAGE; MUC 1; vaccines

Indexed keywords

ANTINEOPLASTIC AGENT; BELAGENPUMATUCEL L; BLP 25 VACCINE; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR VACCINE; GEMCITABINE; MELANOMA ASSOCIATED ANTIGEN A3 VACCINE; NAVELBINE; PEPTIDE VACCINE; PLACEBO; STIMUVAX; TG4010 VACCINE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; AUTOIMMUNITY; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE EDEMA; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; NAUSEA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; TREATMENT OUTCOME;

CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ACTIVE; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80054753255     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.155     Document Type: Review

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Rosell R, Skrzypski M, Jassem E et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2(11), e1129 (2007).
3. Sandler A, Yi J, Dahlberg S, Kolb MM et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carwboplatin for advanced non-small-cell lung cancer. J. Thorac. Oncol. 5(9), 1416-1423 (2010).
4. Gross S, Walden P. Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer? Immunol. Lett. 116(1), 7-14 (2008).
5. Holt GE, Podack ER, Raez LE. Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy 8(1), 43-54 (2011).
6. Kochenderfer JN, Gress RE. A comparison and critical analysis of preclinical anti-cancer vaccination strategies. Exp. Biol. Med. 232, 1130-1141 (2007). (Pubitemid 47503054)
7. Kasid A, Bell GI, Director EP. Effects of transforming growth factor-b on human lymphokine activated killer cell precursors: autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J. Immunol. 141, 690-698 (1988).
8. Tsunawaki S, Sporn M, Ding A et al. Deactivation of macrophages by transforming growth factor-b. Nature 334, 260-262 (1988).
9. Naganuma H, Sasaki A, Satoh E et al. Transforming growth factor-b inhibits interferon-g secretion by lymphokine-activated killer cells stimulated with tumor cells. Neurol. Med. Chir. 36, 789-795 (1996). (Pubitemid 26396633)
10. Kong F, Jirtle RL, Huang DH et al. Plasma transforming growth factor-b1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86, 1712-1719 (1999). (Pubitemid 29513039)
11. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor b-2 antisense gene-modifed allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24, 4721-4730 (2006). (Pubitemid 46630936)
12. Hayes DN, Monti S, Parmigiani G et al. Gene expression profling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J. Clin. Oncol. 24(31), 5079-5090 (2006). (Pubitemid 46631412)
13. Bhattacharjee A, Richards WG, Staunton J et al. Classifcation of human lung carcinomas by mRNA expression profling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA. 98(24), 13790-13795 (2001). (Pubitemid 33115977)
14. Raez LE, Cassileth PA, Schlesselman JJ et al. Allogeneic vaccination with a B7.1 HLA-A gene-modifed adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 22(14), 2800-2807 (2004). (Pubitemid 41079897)
15. Nemunaitis J, Sterman D, Jablons D et al. Granulocyte-macrophage colony-stimulating factor gene-modifed autologous tumor vaccines in non-small-cell lung cancer. J. Natl Cancer Inst. 96(4), 326-331 (2004). (Pubitemid 38256277)
16. Schreiber TH, Deyev V V, Rosenblatt JD, Podack ER. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res. 69(5), 2026-2033 (2009).
17. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100(14), 8372-8377 (2003). (Pubitemid 36842552)
18. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T lymphocyte antigen. J. Clin. Oncol. 23(25), 6043-6053 (2005).
19. Schreiber TH, Raez L, Rosenblatt JD, Podack ER. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin. Immunol. 22(3), 105-112 (2010).
20. González G, Crombet T, Neninger E, Viada C, Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum. Vaccin. 3(1), 8-13 (2007).
21. Gonzalez G, Crombet T, Torres F et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann. Oncol. 14(3), 461-466 (2003). (Pubitemid 36367426)
22. Ramos TC, Vinageras EN, Ferrer MC et al Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol. Ther. 5(2), 145-149 (2006). (Pubitemid 43327531)
23. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105(7), 2862-2868 (2005). (Pubitemid 40446280)
24. Neninger E, Verdecia BG, Crombet T et al Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J. Immunother. 32(1), 92-99 (2009).
25. Sienel W, Varwerk C, Linder A et al Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small-cell lung cancer: results of a multi-center study. Eur. J. Cardiothorac. Surg. 25, 131-134 (2004). (Pubitemid 38019071)
26. + T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol. 172(5), 3289-3296 (2004). (Pubitemid 38263721)
27. Murad YM, Clay TM, Lyerly HK, Morse MA. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin. Biol Ther. 7(8), 1257-1266 (2007). (Pubitemid 47305250)
28. Cooper CL, Davis HL, Morris ML et al CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J. Clin. Immunol 24(6), 693-701 (2004). (Pubitemid 40933121)
29. Vansteenkiste J, Zielinski H, Linder A et al Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the effcacy of MAGE-A3 immu no therapeutic as adjuvant therapy in stage IB/II non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 25(18S), 7554 (2007).
30. Raina D, Kosugi M, Ahmad R et al Dependence on the MUC1-C oncoprotein in non-small-cell lung cancer cells. Mol. Cancer Ther. 10(5), 806-816 (2011).
31. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med. 4, 43-49 (1998). (Pubitemid 28133078)
32. Palmer M, Parker J, Modi S et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specifc immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin. Lung Cancer 3(1), 49-57 (2001). (Pubitemid 32904315)
33. Butts C, Murray N, Maksymiuk A et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23(27), 6674-6681 (2005). (Pubitemid 46190262)
34. Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modifed vaccinia virus (MVA) expressing human MUC1 as antigen-specifc immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med. 5(8), 690-699 (2003). (Pubitemid 40309707)
35. Ramlau R, Quoix E, Rolski J et al. A Phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small-cell lung cancer. J. Thorac. Oncol. 3(7), 735-744 (2008).
36. Acres B, Quoix E, Ramlau R et al. Biomarkers associated with clinical outcome in advanced non-small-cell lung cancer patients treated with TG4010. J. Clin. Oncol. 27, 15s (2009) (Abstract 3027).